Literature DB >> 20527682

Hematology. Allo SCT offers hope as second-line therapy for CML.

Lisa Hutchinson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20527682     DOI： 10.1038/nrclinonc.2010.77

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.

Authors:  Susanne Saussele; Michael Lauseker; Alois Gratwohl; Dietrich W Beelen; Donald Bunjes; Rainer Schwerdtfeger; Hans-Jochem Kolb; Anthony D Ho; Christiane Falge; Ernst Holler; Günter Schlimok; Axel R Zander; Renate Arnold; Lothar Kanz; Robert Dengler; Claudia Haferlach; Brigitte Schlegelberger; Markus Pfirrmann; Martin C Müller; Susanne Schnittger; Armin Leitner; Nadine Pletsch; Andreas Hochhaus; Joerg Hasford; Rüdiger Hehlmann
Journal:  Blood       Date:  2009-11-18       Impact factor: 22.113
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.